The insurance payment of 'Seretide' for the treatment has asthma and COPD (chronic obstructive pulmonary disease), was enlarged
GlaxoSmithKline announced that the insurance payment of 'Seretide' which was approved for the treatment has asthma and COPD (chronic obstructive pulmonary disease), was enlarged starting from January 2014.
Ministry of Health and Welfare expanded the insurance payment of 'Seretide' from previous ...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
